Krystal Biotech Inc (KRYS) — Cash Flow Quality Index

Latest as of June 2026: 1.37x

Krystal Biotech Inc (KRYS) has a Cash Flow Quality Index of 1.37x as of June 2026. Operating cash flow of $74.79 Million exceeds net income of $54.77 Million, indicating high earnings quality where cash backs reported profits. Explore debt repayment capacity of Krystal Biotech Inc to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

1.37x
Operating CF / Net Income

Operating Cash Flow

$74.79 Million
USD

Net Income

$54.77 Million
USD

Data as of

Jun 2026
Most recent filing

Krystal Biotech Inc Cash Flow Quality Index (2023–2025)

Historical Cash Flow Quality Index for Krystal Biotech Inc across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash flow conversion of Krystal Biotech Inc.

Annual Cash Flow Quality Index for Krystal Biotech Inc (2023–2025)

Year-by-year earnings quality comparison for Krystal Biotech Inc.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 0.98x $200.87 Million $204.83 Million ▼ -29.2%
2024 1.38x $123.42 Million $89.16 Million ▲ +117.0%
2023 -8.12x $-88.80 Million $10.93 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.